BIOMARKERS CORRELATED TO PARP INHIBITOR TREATMENT SUCCESS IN AML PATIENTS

Maria Teresa Esposito (Inventor)

Research output: Patent

21 Downloads (Pure)

Abstract

In one aspect, there is provided a method for predicting responsiveness of a subject to a poly-(ADP-ribose)-polymerase (PARP) inhibitor for treating acute myeloid leukaemia (AML), the method comprising determining whether a chromosomal abnormality selected from t(8;21), t(15;17), t(16;16) and inv(16) is present in a sample obtained from the subject; wherein the presence of the chromosomal abnormality is indicative of responsiveness of the subject to the PARP inhibitor for treating AML
Original languageEnglish
Patent number514/34
IPCC12Q1/68; A61K31/4184; A61K31/502; A61K45/06
Priority date17/09/14
Publication statusPublished - 21 Jul 2016

Keywords

  • biomarkers
  • leukemia
  • PARP inhibitor
  • DNA damage

Cite this